MedTrace Logo

CB1 Receptor PET Imaging Reveals Gender Differences in PTSD

NCT02237677 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2016-08-17

No results posted yet for this study

Summary

The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling.

Conditions

  • Post-traumatic Stress Disorder (PTSD)

Interventions

OTHER

Positron emission tomography (PET) imaging

Positron emission tomography (PET) imaging

Sponsors & Collaborators

Principal Investigators

  • Charles Marmar, MD · NYU School of Medicine

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237677 on ClinicalTrials.gov